VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors

Name

VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors

Accession Number

DBCAT005731

Description

Not Available

ATC Classification

Drugs

Drug	Drug Description
Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
Ramucirumab	An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.

Drugs & Drug Targets

Drug	Target	Type
Bevacizumab	Vascular endothelial growth factor A	target
Bevacizumab	Complement C1q subcomponent subunit A	target
Bevacizumab	Complement C1q subcomponent subunit B	target
Bevacizumab	Complement C1q subcomponent subunit C	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Bevacizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
Bevacizumab	High affinity immunoglobulin gamma Fc receptor I	target
Ramucirumab	Vascular endothelial growth factor receptor 2	target